These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 16754631

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy.
    Colombo GL, Caruggi M, Ottolini C, Maggioni AP.
    Vasc Health Risk Manag; 2008; 4(1):223-34. PubMed ID: 18629370
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 4. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin inhibition in heart failure.
    McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 26; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [Abstract] [Full Text] [Related]

  • 6. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May 26; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 7. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM Investigators.
    Eur Heart J; 2008 Dec 26; 29(24):3022-8. PubMed ID: 18987098
    [Abstract] [Full Text] [Related]

  • 8. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
    Plosker GL, Keam SJ.
    Pharmacoeconomics; 2006 Dec 26; 24(12):1249-72. PubMed ID: 17129078
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
    Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG, CHARM Investigators and Committees.
    Eur J Heart Fail; 2007 May 26; 9(5):510-7. PubMed ID: 17317308
    [Abstract] [Full Text] [Related]

  • 10. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program.
    Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S.
    Am Heart J; 2011 Nov 26; 162(5):900-6. PubMed ID: 22093207
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    Chang SM, Granger CB, Johansson PA, Kosolcharoen P, McMurray JJ, Michelson EL, Murray DR, Olofsson B, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S, Dunlap ME, CHARM Investigators.
    Eur J Heart Fail; 2010 Jul 26; 12(7):738-45. PubMed ID: 20418272
    [Abstract] [Full Text] [Related]

  • 12. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
    O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA.
    Eur J Heart Fail; 2005 Jun 26; 7(4):650-6. PubMed ID: 15921807
    [Abstract] [Full Text] [Related]

  • 13. [Clinical study of the month. The CHARM study].
    Kulbertus H.
    Rev Med Liege; 2003 Oct 26; 58(10):646-52. PubMed ID: 14677527
    [Abstract] [Full Text] [Related]

  • 14. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA.
    Circulation; 2004 Oct 12; 110(15):2180-3. PubMed ID: 15466644
    [Abstract] [Full Text] [Related]

  • 15. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD, CHARM Investigators.
    J Am Coll Cardiol; 2012 May 15; 59(20):1785-95. PubMed ID: 22575317
    [Abstract] [Full Text] [Related]

  • 16. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, CHARM Investigators.
    Eur Heart J; 2008 Jun 15; 29(11):1377-85. PubMed ID: 18413309
    [Abstract] [Full Text] [Related]

  • 17. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S, Wang D, Wilhelmsen L, Hennekens CH.
    Am Heart J; 2005 May 15; 149(5):939-43. PubMed ID: 15894981
    [Abstract] [Full Text] [Related]

  • 18. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 15; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 15; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 20. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.
    Circulation; 2006 Feb 07; 113(5):671-8. PubMed ID: 16461840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.